Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

345 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Should omalizumab be used in severe asthma/COPD overlap?
Sposato B, Scalese M, Milanese M, Masieri S, Cavaliere C, Ricci A, Paggiaro P. Sposato B, et al. Among authors: paggiaro p. J Biol Regul Homeost Agents. 2018 Jul-Aug;32(4):755-761. J Biol Regul Homeost Agents. 2018. PMID: 30043557
Different Skin Prick Test Sensitization Patterns Do Not Influence the Response to Omalizumab in Severe Asthma.
Sposato B, Scalese M, Milanese M, Masieri S, Cavaliere C, Latorre M, Scichilone N, Matucci A, Vultaggio A, Ricci A, Cresti A, Paggiaro PL. Sposato B, et al. Among authors: paggiaro pl. J Investig Allergol Clin Immunol. 2017;27(6):388-391. doi: 10.18176/jiaci.0196. J Investig Allergol Clin Immunol. 2017. PMID: 29199967 Free article. No abstract available.
Factors reducing omalizumab response in severe asthma.
Sposato B, Scalese M, Milanese M, Masieri S, Cavaliere C, Latorre M, Scichilone N, Matucci A, Vultaggio A, Ricci A, Cresti A, Santus P, Perrella A, Paggiaro PL. Sposato B, et al. Among authors: paggiaro pl. Eur J Intern Med. 2018 Jun;52:78-85. doi: 10.1016/j.ejim.2018.01.026. Epub 2018 Feb 1. Eur J Intern Med. 2018. PMID: 29395935
Real-life Mepolizumab effectiveness in severe eosinophilic asthmatics with nasal polyposis.
Sposato B, Scalese M, Camiciottoli G, Carpagnano GE, Pelaia C, Santus P, Maniscalco M, Corsico A, Grosso A, Baglioni S, Murgia N, Folletti I, Pelaia G, Masieri S, Cavaliere C, Musarra A, Bargagli E, Ricci A, Latorre M, Rogliani P, Paggiaro P. Sposato B, et al. Among authors: paggiaro p. Respir Med Res. 2020 Nov;78:100791. doi: 10.1016/j.resmer.2020.100791. Epub 2020 Sep 21. Respir Med Res. 2020. PMID: 33039948 No abstract available.
Characteristics and treatment regimens across ERS SHARP severe asthma registries.
van Bragt JJMH, Adcock IM, Bel EHD, Braunstahl GJ, Ten Brinke A, Busby J, Canonica GW, Cao H, Chung KF, Csoma Z, Dahlén B, Davin E, Hansen S, Heffler E, Horvath I, Korn S, Kots M, Kuna P, Kwon N, Louis R, Plaza V, Porsbjerg C, Ramos-Barbon D, Richards LB, Škrgat S, Sont JK, Vijverberg SJH, Weersink EJM, Yasinska V, Wagers SS, Djukanovic R, Maitland-van der Zee AH; SHARP Clinical Research Collaboration; Members of the SHARP Clinical Research Collaboration are. van Bragt JJMH, et al. Eur Respir J. 2020 Jan 9;55(1):1901163. doi: 10.1183/13993003.01163-2019. Print 2020 Jan. Eur Respir J. 2020. PMID: 31601713 Free article.
Formoterol by pressurized metered-dose aerosol or dry powder on airway obstruction and lung hyperinflation in partially reversible COPD.
Brusasco V, Canonica GW, Dal Negro R, Scano G, Paggiaro P, Fabbri LM, Barisione G, D'Amato G, Varoli G, Baroffio M, Milanese M, Mereu C, Crimi E. Brusasco V, et al. Among authors: paggiaro p. J Aerosol Med Pulm Drug Deliv. 2011 Oct;24(5):235-43. doi: 10.1089/jamp.2010.0862. Epub 2011 Jun 20. J Aerosol Med Pulm Drug Deliv. 2011. PMID: 21689019 Clinical Trial.
Economic impact of mepolizumab in uncontrolled severe eosinophilic asthma, in real life.
Bagnasco D, Povero M, Pradelli L, Brussino L, Rolla G, Caminati M, Menzella F, Heffler E, Canonica GW, Paggiaro P, Senna G, Milanese M, Lombardi C, Bucca C, Manfredi A, Canevari RF, Passalacqua G; SANI Network (Severe Asthma Network Italy). Bagnasco D, et al. Among authors: paggiaro p. World Allergy Organ J. 2021 Jan 27;14(2):100509. doi: 10.1016/j.waojou.2021.100509. eCollection 2021 Feb. World Allergy Organ J. 2021. PMID: 33598095 Free PMC article.
Potential benefit of omalizumab in respiratory diseases.
Bonini M, Di Maria G, Paggiaro P, Rossi A, Senna G, Triggiani M, Canonica GW. Bonini M, et al. Among authors: paggiaro p. Ann Allergy Asthma Immunol. 2014 Nov;113(5):513-9. doi: 10.1016/j.anai.2014.06.031. Epub 2014 Nov 5. Ann Allergy Asthma Immunol. 2014. PMID: 25442695 Review.
RItA: The Italian severe/uncontrolled asthma registry.
Maio S, Baldacci S, Bresciani M, Simoni M, Latorre M, Murgia N, Spinozzi F, Braschi M, Antonicelli L, Brunetto B, Iacovacci P, Roazzi P, Pini C, Pata M, La Grasta L, Paggiaro P, Viegi G; AGAVE group. Maio S, et al. Among authors: paggiaro p. Allergy. 2018 Mar;73(3):683-695. doi: 10.1111/all.13342. Epub 2017 Nov 22. Allergy. 2018. PMID: 29072882
345 results